Avelox

Moxifloxacin HCl

Community acquired pneumonia caused by susceptible isolates of Strep pneumoniae (including multi-drug resistant Strep pneumoniae), H. influenzae, Moraxella catarrhalis, methicillin-susceptible Staph aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae; uncomplicated skin & skin structure infections caused by susceptible isolates of methicillin-susceptible Staph aureus or Strep pyogenes; complicated skin & skin structure infections caused by susceptible isolates of methicillin-susceptible Staph aureus, E. coli, Klebsiella pneumoniae, or Enterobacter cloacae; complicated intra-abdominal infections including polymicrobial infections eg, abscess caused by susceptible isolates of E. coli, Bacteroides fragilis, Strep anginosus, Strep constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species; acute bacterial sinusitis caused by susceptible isolates of Strep pneumoniae, H. influenzae, or Moraxella catarrhalis; acute bacterial exacerbation of chronic bronchitis caused by susceptible isolates of Strep pneumoniae, H. influenzae, H. parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staph aureus, or Moraxella catarrhalis.

PO or IV infusion Adult Community acquired pneumonia 400 mg once every 24 hr for 7-14 days. Uncomplicated skin & skin structure infections 400 mg once every 24 hr for 7 days. Complicated skin & skin structure infections 400 mg once every 24 hr for 7-21 days. Complicated intra-abdominal infections 400 mg once every 24 hr for 5-14 days. Acute bacterial sinusitis 400 mg once every 24 hr for 10 days. Acute bacterial exacerbation of chronic bronchitis 400 mg once every 24 hr for 5 days.

May be taken with or without food.

Hypersensitivity to moxifloxacin or any quinolone antibacterials. Patients w/ congenital or documented acquired QT prolongation; electrolyte disturbances, particularly in uncorrected hypokalaemia; clinically relevant bradycardia; clinically relevant heart failure w/ reduced left-ventricular ejection fraction; previous history of symptomatic arrhythmias. Should not be used concurrently w/ other drugs that prolong QT interval.

Associated w/ disabling & potentially irreversible serious adverse reactions from different body systems; discontinue immediately at 1st signs or symptoms of any serious adverse reaction. Increased risk of tendinitis & tendon rupture; peripheral neuropathy; psychiatric adverse reactions (including toxic psychosis, hallucinations, or paranoia; depression or suicidal thoughts or acts; anxiety, agitation, or nervousness; confusion, delirium, disorientation, or disturbances in attention; insomnia or nightmares; memory impairment); CNS reactions (including convulsions, increased intracranial pressure, dizziness, tremors). May exacerbate muscle weakness in patients w/ myasthenia gravis. QTc prolongation in some patients. Discontinue immediately at 1st appearance of skin rash, jaundice, or any other sign of hypersensitivity. Reports of cases of fulminant hepatitis; increased rate of aortic aneurysm & dissection w/in 2 mth following use of fluoroquinolones, particularly in elderly patients; Clostridioides difficile-associated diarrhea; disturbances in blood glucose. Avoid excessive sun or UV light exposure. Consult an eye specialist in case of vision disorders. May cause fetal harm. Pregnancy & lactation. Childn & adolescents <18 yr. Elderly.

Nausea, diarrhea; headache, dizziness. Anemia; vomiting, constipation, abdominal pain, dyspepsia; pyrexia; increased ALT; hypokalemia; insomnia.

Additive effect on QT prolongation w/ anti-arrhythmics class IA (eg, quinidine, hydroquinidine, disopyramide); anti-arrhythmics class III (eg, amiodarone, sotalol, dofetilide, ibutilide); antipsychotics (eg, phenothiazines, pimozide, sertindole, haloperidol, sultopride); TCAs; certain antimicrobial agents (sparfloxacin, erythromycin IV, pentamidine, antimalarials particularly halofantrine); certain antihistamine (terfenadine, astemizole, mizolastine); cisapride, vincamine IV, bepridil, diphemanil. Enhanced anticoagulant effects of warfarin or its derivatives. Disturbances of blood glucose w/ antidiabetics. Increased risk of CNS stimulation & convulsions w/ NSAIDs. Oral: Interference in absorption w/ antacids containing Al or Mg; sucralfate; metal cations eg, Fe; multivit containing Fe or Zn; formulations containing divalent & trivalent cations.

Quinolones

J01MA14 - moxifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.

P₁S₁S₃